TG Therapeutics (TGTX) Financials

$35.75 +0.64 (+1.82%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$35.75 0.00 (0.00%)

As of 05:23 AM Eastern

Annual Income Statements for TG Therapeutics

This table shows TG Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	23	13	-224	-348	-279	-173	-173	-118	-78	-63
Consolidated Net Income / (Loss)	23	13	-224	-348	-279	-173	-173	-118	-78	-63
Net Income / (Loss) Continuing Operations	23	13	-224	-348	-279	-173	-173	-118	-78	-63
Total Pre-Tax Income	26	13	-224	-348	-279	-173	-173	-118	-78	-63
Total Operating Income	42	21	-218	-345	-274	-169	-174	-119	-79	-63
Total Gross Profit	291	220	2.79	5.90	0.15	0.15	0.15	0.15	0.15	0.15
Total Revenue	329	234	2.79	6.69	0.15	0.15	0.15	0.15	0.15	0.15
Operating Revenue	329	234	2.79	6.69	0.15	0.15	0.15	0.15	0.15	0.15
Total Cost of Revenue	38	14	0.00	0.79	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	38	14	-	0.79	0.00	0.00	-	-	-	-
Total Operating Expenses	249	199	221	351	274	169	175	119	79	63
Selling, General & Admin Expense	154	123	95	128	108	15	15	16	9.89	16
Research & Development Expense	94	76	125	223	166	154	159	103	69	48
Total Other Income / (Expense), net	-16	-7.57	-5.50	-3.33	-5.79	-3.82	0.92	0.24	0.72	0.23
Interest Expense	24	13	10	5.64	6.33	5.29	0.88	0.85	-	-
Other Income / (Expense), net	7.69	5.04	4.70	2.31	0.54	1.47	1.80	1.08	0.39	0.06
Income Tax Expense	2.21	0.39	0.00	0.00	-	-	-	-	-	-
Basic Earnings per Share	$0.16	$0.09	($1.65)	($2.63)	($2.42)	($1.96)	($2.30)	($1.91)	($1.60)	($1.38)
Weighted Average Basic Shares Outstanding	145.32M	141.96M	135.41M	132.22M	115.33M	88.37M	75.47M	62.07M	49.04M	45.65M
Diluted Earnings per Share	$0.15	$0.09	($1.65)	($2.63)	($2.42)	($1.96)	($2.30)	($1.91)	($1.60)	($1.38)
Weighted Average Diluted Shares Outstanding	160.34M	148.51M	135.41M	132.22M	115.33M	88.37M	75.47M	62.07M	49.04M	45.65M
Weighted Average Basic & Diluted Shares Outstanding	157.07M	154.42M	146.36M	132.22M	115.33M	88.37M	75.47M	62.07M	49.04M	45.65M

This table shows TG Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	23	3.88	6.88	-11	-14	114	-48	-39	-78	-36
Consolidated Net Income / (Loss)	23	3.88	6.88	-11	-14	114	-48	-39	-78	-36
Net Income / (Loss) Continuing Operations	23	3.88	6.88	-11	-14	114	-48	-39	-78	-36
Total Pre-Tax Income	25	4.27	6.55	-11	-14	114	-48	-39	-78	-36
Total Operating Income	30	12	8.82	-9.27	-12	115	-45	-37	-78	-35
Total Gross Profit	83	84	65	58	34	162	16	6.95	0.34	0.09
Total Revenue	108	84	73	63	44	166	16	7.80	0.08	0.09
Operating Revenue	108	84	73	63	44	166	16	7.80	0.08	0.09
Total Cost of Revenue	25	0.00	8.30	5.44	9.77	3.51	0.00	0.86	-0.26	0.00
Total Operating Expenses	53	71	56	67	47	48	61	44	78	35
Selling, General & Admin Expense	39	42	39	35	31	33	31	28	48	14
Research & Development Expense	24	20	18	33	17	15	28	16	30	21
Total Other Income / (Expense), net	-4.50	-8.17	-2.27	-1.41	-1.54	-0.85	-2.94	-2.24	-0.93	-0.86
Interest Expense	6.93	11	3.98	2.29	2.43	3.71	3.63	2.84	2.86	1.65
Other Income / (Expense), net	2.44	2.67	1.71	0.88	0.89	2.86	0.69	0.60	1.93	0.79
Income Tax Expense	2.12	0.39	-0.33	0.03	0.39	0.00	0.00	0.00	-	-
Basic Earnings per Share	$0.15	$0.03	$0.05	($0.07)	($0.09)	$0.80	($0.34)	($0.28)	($0.58)	($0.26)
Weighted Average Basic Shares Outstanding	145.32M	145.10M	144.73M	146.21M	141.96M	142.87M	141.50M	140.31M	135.41M	135.33M
Weighted Average Diluted Shares Outstanding	160.34M	160.71M	159.42M	154.54M	148.51M	155.87M	141.50M	149.40M	135.41M	135.33M
Weighted Average Basic & Diluted Shares Outstanding	157.07M	155.67M	154.82M	154.54M	154.42M	151.41M	150.98M	149.40M	146.36M	145.34M

This table details how cash moves in and out of TG Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	87	-9.36	-197	-255	441	71	-14	32	-30	-0.65
Net Cash From Operating Activities	-41	-31	-176	-296	-215	-133	-129	-94	-63	-45
Net Cash From Continuing Operating Activities	-41	-31	-176	-296	-215	-133	-129	-94	-62	-45
Net Income / (Loss) Continuing Operations	23	13	-224	-348	-279	-173	-173	-118	-78	-63
Consolidated Net Income / (Loss)	23	13	-224	-348	-279	-173	-173	-118	-78	-63
Depreciation Expense	0.07	0.21	0.30	0.28	0.16	0.10	0.09	0.08	0.06	0.02
Amortization Expense	-4.78	0.35	1.73	1.81	1.11	0.70	0.02	0.19	0.46	0.54
Non-Cash Adjustments To Reconcile Net Income	50	38	45	63	83	14	17	16	5.33	16
Changes in Operating Assets and Liabilities, net	-109	-82	0.69	-12	-20	25	28	8.44	11	2.07
Net Cash From Investing Activities	-1.04	-51	-20	-0.33	-25	-0.72	1.18	-8.21	27	-25
Net Cash From Continuing Investing Activities	-1.04	-51	-20	-0.33	-25	-0.72	1.18	-8.21	27	-25
Purchase of Property, Plant & Equipment	-0.05	0.00	-0.01	-0.40	-0.36	-0.13	-0.09	-0.00	-0.34	-0.04
Purchase of Investments	-312	-147	-107	-56	-67	-30	-31	-28	-15	-49
Sale and/or Maturity of Investments	311	96	87	56	43	29	33	20	42	24
Net Cash From Financing Activities	129	73	-0.39	41	680	204	114	134	5.02	69
Net Cash From Continuing Financing Activities	129	73	-0.39	41	680	204	114	134	5.02	69
Repayment of Debt	-0.89	-0.13	-0.98	-1.02	0.00	-0.80	0.00	-	-0.01	-
Repurchase of Common Equity	-8.76	0.00	0.00	-	-	-	-	-	-	-
Issuance of Debt	245	25	0.00	70	0.00	30	0.00	0.00	-	0.10
Issuance of Common Equity	0.00	46	0.00	2.22	-	-	0.00	-	-	-
Other Financing Activities, net	-107	1.53	0.58	-30	680	175	114	134	5.03	69
Cash Interest Paid	18	8.77	5.45	3.47	-	-	-	-	-	-
Cash Income Taxes Paid	0.50	0.00	0.00	-	-	-	-	-	-	-

This table details how cash moves in and out of TG Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-16	113	7.44	-17	-58	54	36	-41	-7.55	-37
Net Cash From Operating Activities	-26	-12	5.54	-8.21	-13	84	-42	-60	-24	-34
Net Cash From Continuing Operating Activities	-26	-12	5.54	-8.21	-13	84	-42	-60	-24	-34
Net Income / (Loss) Continuing Operations	23	3.88	6.88	-11	-14	114	-48	-39	-78	-36
Consolidated Net Income / (Loss)	23	3.88	6.88	-11	-14	114	-48	-39	-78	-36
Depreciation Expense	0.01	0.01	0.02	0.03	0.04	0.07	0.03	0.07	0.07	0.08
Amortization Expense	-1.34	-1.35	-1.11	-0.98	-0.84	0.48	0.51	0.21	0.36	0.36
Non-Cash Adjustments To Reconcile Net Income	13	17	10	9.52	9.46	7.56	14	6.78	35	8.21
Changes in Operating Assets and Liabilities, net	-61	-32	-11	-6.07	-7.46	-38	-8.77	-28	19	-7.33
Net Cash From Investing Activities	16	-9.33	1.77	-9.26	-45	-30	31	-6.17	16	-2.99
Net Cash From Continuing Investing Activities	16	-9.33	1.77	-9.26	-45	-30	31	-6.17	16	-2.99
Purchase of Property, Plant & Equipment	-0.02	-	-	-	-	-	-	-	-0.00	-0.00
Purchase of Investments	-58	-102	-70	-83	-68	-56	-	-22	-4.00	-31
Sale and/or Maturity of Investments	74	92	71	73	24	26	31	16	20	28
Net Cash From Financing Activities	-6.07	134	0.14	0.01	-0.00	0.42	47	25	0.05	0.28
Net Cash From Continuing Financing Activities	-6.07	134	0.14	0.01	-0.00	0.42	47	25	0.05	0.28
Repayment of Debt	108	-108	-	0.00	-	-	-	-0.13	-0.98	0.98
Repurchase of Common Equity	-6.61	-	-	-	-	-	-	-	-	-
Other Financing Activities, net	-107	0.20	0.14	0.01	-	0.42	0.75	0.36	1.02	-0.70
Cash Interest Paid	6.42	7.11	2.49	2.45	4.84	-	2.18	1.75	1.54	-

This table presents TG Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	578	330	194	380	626	163	84	97	55	113
Total Current Assets	566	318	168	331	612	149	79	93	51	87
Cash & Equivalents	180	93	102	299	553	113	42	57	25	55
Short-Term Investments	131	125	59	16	52	28	27	28	20	22
Accounts Receivable	129	51	0.00	1.39	0.00	-	-	-	-	-
Inventories, net	110	40	0.00	-	-	-	-	-	-	-
Other Current Assets	16	9.52	2.36	2.88	1.08	0.61	0.44	0.44	0.22	0.31
Plant, Property, & Equipment, net	0.00	0.00	0.31	0.60	0.48	0.28	0.25	0.25	0.33	0.05
Total Noncurrent Assets	11	12	25	48	13	14	4.33	3.82	3.59	27
Long-Term Investments	0.81	0.00	12	36	0.00	-	-	-	-	25
Other Noncurrent Operating Assets	11	12	10	9.89	11	11	1.24	-	0.16	0.17
Total Liabilities & Shareholders' Equity	578	330	194	380	626	163	84	97	55	113
Total Liabilities	355	169	135	142	106	124	60	30	19	12
Total Current Liabilities	91	54	53	65	88	84	39	28	17	11
Accounts Payable	58	38	42	51	37	30	36	26	15	9.35
Current Deferred Revenue	11	0.15	-	-	-	-	-	0.15	0.15	0.15
Current Employee Benefit Liabilities	15	12	8.43	10	8.46	3.80	2.26	1.80	1.39	0.82
Other Current Liabilities	5.78	2.93	2.75	2.95	20	51	0.22	-	-	-
Total Noncurrent Liabilities	265	115	82	77	19	40	21	2.43	2.04	1.37
Long-Term Debt	244	100	71	67	7.72	29	0.00	-	-	-
Noncurrent Deferred Revenue	12	6.02	0.31	0.46	0.61	0.76	2.38	2.43	2.04	1.37
Other Noncurrent Operating Liabilities	8.13	9.23	10	9.85	10	10	18	0.00	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	222	161	59	237	519	39	24	67	36	102
Total Preferred & Common Equity	222	161	59	237	519	39	24	67	36	102
Total Common Equity	222	161	59	237	519	39	24	67	36	102
Common Stock	1,761	1,713	1,586	1,566	1,500	740	553	422	272	260
Retained Earnings	-1,529	-1,553	-1,527	-1,329	-981	-701	-528	-355	-236	-158
Treasury Stock	-8.99	-0.23	-0.23	-0.23	-0.23	-0.23	-0.23	-0.23	-0.23	-0.23

This table presents TG Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	586	401	373	331	221	197	218
Total Current Assets	574	389	361	319	209	185	183
Cash & Equivalents	196	83	75	151	97	61	110
Short-Term Investments	145	134	134	78	48	78	66
Accounts Receivable	116	84	65	39	17	8.62	0.00
Inventories, net	85	81	78	34	30	27	-
Other Current Assets	33	7.05	8.10	12	11	4.46	2.95
Plant, Property, & Equipment, net	0.00	0.00	0.07	0.13	0.21	0.24	0.38
Total Noncurrent Assets	12	12	13	12	12	12	35
Long-Term Investments	1.13	0.95	1.32	0.00	0.00	0.00	22
Other Noncurrent Operating Assets	11	11	9.20	9.55	9.75	9.97	10
Total Liabilities & Shareholders' Equity	586	401	373	331	221	197	218
Total Liabilities	394	224	213	166	180	170	117
Total Current Liabilities	125	109	100	58	73	63	36
Accounts Payable	101	93	87	40	63	57	30
Current Deferred Revenue	9.09	3.37	3.37	6.90	-	-	-
Current Employee Benefit Liabilities	10	6.35	3.60	8.34	6.64	3.22	4.30
Other Current Liabilities	4.53	5.47	5.45	2.70	3.08	2.77	2.42
Total Noncurrent Liabilities	269	115	114	109	108	107	81
Long-Term Debt	244	103	101	99	98	97	70
Noncurrent Deferred Revenue	16	3.74	3.24	0.19	0.23	0.27	0.34
Other Noncurrent Operating Liabilities	8.42	8.70	8.96	9.52	9.81	10	11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	192	178	160	165	40	27	100
Total Preferred & Common Equity	192	178	160	165	40	27	100
Total Common Equity	192	178	160	165	40	27	100
Common Stock	1,747	1,734	1,685	1,665	1,655	1,594	1,575
Retained Earnings	-1,553	-1,556	-1,525	-1,500	-1,614	-1,566	-1,474
Treasury Stock	-2.38	-0.23	-0.23	-0.23	-0.23	-0.23	-

This table displays calculated financial ratios and metrics derived from TG Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	40.80%	8,290.02%	-58.36%	4,300.66%	0.00%	0.00%	0.00%	0.00%	-0.25%	0.00%
EBITDA Growth	71.15%	112.40%	37.83%	-25.24%	-62.95%	3.31%	-46.98%	-50.36%	-24.74%	-12.46%
EBIT Growth	93.25%	112.02%	37.62%	-25.42%	-62.93%	2.91%	-46.73%	-49.70%	-24.48%	-13.05%
NOPAT Growth	91.37%	113.10%	36.68%	-26.02%	-61.84%	3.06%	-46.91%	-50.33%	-24.99%	-13.39%
Net Income Growth	84.52%	105.66%	35.70%	-24.60%	-61.61%	0.35%	-46.43%	-51.40%	-24.31%	-12.85%
EPS Growth	66.67%	105.45%	37.26%	-8.68%	-23.47%	14.78%	-20.42%	-19.38%	-15.94%	15.85%
Operating Cash Flow Growth	-28.98%	82.17%	40.41%	-37.82%	-61.52%	-3.01%	-37.51%	-48.46%	-41.31%	-27.47%
Free Cash Flow Firm Growth	-9.06%	56.15%	38.99%	-21.11%	-130.41%	5.29%	-28.14%	-59.17%	-10.90%	5.12%
Invested Capital Growth	259.49%	197.19%	2.25%	19.23%	22.88%	-62.38%	-146.74%	-90.76%	-829.77%	-199.89%
Revenue Q/Q Growth	24.25%	23.13%	-44.58%	51.82%	0.00%	0.00%	0.00%	0.19%	-0.25%	0.00%
EBITDA Q/Q Growth	2,967.83%	337.16%	7.22%	-1.52%	-22.07%	38.53%	-186.50%	-5.45%	-7.40%	1.88%
EBIT Q/Q Growth	779.36%	299.67%	7.23%	-1.58%	-22.01%	38.36%	-185.42%	-5.48%	-7.27%	1.72%
NOPAT Q/Q Growth	10,936.45%	250.94%	6.59%	-1.82%	-21.72%	38.29%	-178.61%	-6.27%	-8.80%	1.68%
Net Income Q/Q Growth	262.79%	148.92%	6.23%	-1.49%	-21.08%	37.24%	-178.92%	-6.46%	-8.40%	1.85%
EPS Q/Q Growth	0.00%	0.00%	6.78%	1.50%	-15.24%	42.52%	-158.43%	1.55%	-8.11%	9.80%
Operating Cash Flow Q/Q Growth	-44.26%	25.34%	26.35%	-13.38%	-11.22%	7.10%	-16.96%	-3.61%	-9.89%	4.70%
Free Cash Flow Firm Q/Q Growth	-22.64%	10.02%	19.16%	-6.40%	-19.47%	39.01%	-224.80%	-6.65%	-2.05%	7.55%
Invested Capital Q/Q Growth	64.62%	24.90%	-63.15%	15.78%	-4.36%	-2.97%	-65.27%	-43.17%	-121.03%	-254.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.30%	93.95%	100.00%	88.19%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	13.65%	11.23%	-7,597.59%	-5,088.53%	-178,804.61%	-109,728.29%	-113,487.50%	-77,212.50%	-51,351.32%	-41,062.67%
Operating Margin	12.74%	8.83%	-7,838.99%	-5,154.28%	-179,996.05%	-111,220.39%	-114,736.84%	-78,100.00%	-51,953.29%	-41,461.87%
EBIT Margin	15.08%	10.99%	-7,670.41%	-5,119.79%	-179,639.47%	-110,252.63%	-113,555.92%	-77,388.82%	-51,694.74%	-41,424.65%
Profit (Net Income) Margin	7.11%	5.42%	-8,036.34%	-5,204.08%	-183,803.29%	-113,730.92%	-114,132.89%	-77,944.74%	-51,482.24%	-41,310.04%
Tax Burden Percent	91.36%	97.01%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	51.58%	50.87%	104.77%	101.65%	102.32%	103.15%	100.51%	100.72%	99.59%	99.72%
Effective Tax Rate	8.64%	2.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	38.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8,197,592.44%
ROIC Less NNEP Spread (ROIC-NNEP)	54.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8,197,571.83%
Return on Net Nonoperating Assets (RNNOA)	-26.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,197,523.14%
Return on Equity (ROE)	12.21%	11.57%	-151.36%	-92.03%	-100.14%	-551.85%	-381.16%	-230.36%	-113.87%	-69.30%
Cash Return on Invested Capital (CROIC)	-74.27%	-156.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	10.94%	9.82%	-74.54%	-68.13%	-69.24%	-135.90%	-190.73%	-154.61%	-93.40%	-63.05%
Return on Assets (ROA)	5.15%	4.84%	-78.09%	-69.26%	-70.85%	-140.19%	-191.70%	-155.72%	-93.02%	-62.88%
Return on Common Equity (ROCE)	12.21%	11.57%	-151.36%	-92.03%	-100.14%	-551.85%	-381.16%	-230.36%	-113.87%	-69.30%
Return on Equity Simple (ROE_SIMPLE)	10.52%	7.90%	-382.02%	-146.78%	-53.79%	-447.68%	-721.76%	-176.85%	-218.17%	-61.97%
Net Operating Profit after Tax (NOPAT)	38	20	-153	-241	-192	-118	-122	-83	-55	-44
NOPAT Margin	11.64%	8.57%	-5,487.30%	-3,608.00%	-125,997.24%	-77,854.28%	-80,315.79%	-54,670.00%	-36,367.30%	-29,023.31%
Net Nonoperating Expense Percent (NNEP)	-16.15%	-6.67%	-36.83%	-24.88%	-25.58%	-60.47%	-66.72%	-54.19%	-31.05%	-20.61%
Return On Investment Capital (ROIC_SIMPLE)	8.21%	7.68%	-117.81%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	11.70%	6.05%	0.00%	11.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	46.90%	52.51%	3,428.51%	1,914.94%	70,953.95%	9,886.18%	9,974.34%	10,744.08%	6,505.92%	10,254.02%
R&D to Revenue	28.66%	32.61%	4,500.97%	3,327.54%	109,142.11%	101,434.21%	104,862.50%	67,455.92%	45,547.37%	31,307.86%
Operating Expenses to Revenue	75.56%	85.12%	7,938.99%	5,242.47%	180,096.05%	111,320.39%	114,836.84%	78,200.00%	52,053.29%	41,561.87%
Earnings before Interest and Taxes (EBIT)	50	26	-214	-342	-273	-168	-173	-118	-79	-63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	45	26	-212	-340	-272	-167	-173	-117	-78	-63
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	21.07	16.11	29.35	11.45	13.17	28.62	14.14	8.65	7.10	6.17
Price to Tangible Book Value (P/TBV)	21.07	16.11	29.75	11.49	13.19	29.22	14.63	8.75	7.26	6.22
Price to Revenue (P/Rev)	14.24	11.07	617.38	406.03	45,000.79	7,270.60	2,236.04	3,811.50	1,674.34	4,111.80
Price to Earnings (P/E)	200.38	204.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.50%	0.49%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	29.80	57.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	14.04	10.57	580.41	363.79	41,214.40	6,537.28	1,782.75	3,255.00	1,379.50	3,442.30
Enterprise Value to EBITDA (EV/EBITDA)	102.82	94.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	93.07	96.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	120.56	123.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.10	0.62	1.21	0.29	0.06	0.75	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	1.10	0.62	1.21	0.28	0.01	0.75	0.00	0.00	0.00	0.00
Financial Leverage	-0.48	-1.01	-1.30	-1.13	-1.23	-2.88	-1.69	-1.27	-1.08	-1.00
Leverage Ratio	2.37	2.39	1.94	1.33	1.41	3.94	1.99	1.48	1.22	1.10
Compound Leverage Factor	1.22	1.21	2.03	1.35	1.45	4.06	2.00	1.49	1.22	1.10
Debt to Total Capital	52.36%	38.42%	54.84%	22.22%	5.44%	42.86%	0.00%	0.19%	0.19%	0.21%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.32%	4.04%	0.00%	0.00%	0.19%	0.19%	0.21%
Long-Term Debt to Total Capital	52.36%	38.42%	54.84%	21.90%	1.40%	42.86%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	47.64%	61.58%	45.16%	77.78%	94.56%	57.14%	100.00%	99.81%	99.81%	99.79%
Debt to EBITDA	5.44	3.82	-0.34	-0.20	-0.11	-0.17	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-1.50	-4.47	0.49	0.83	2.12	0.67	0.00	0.72	0.57	1.63
Long-Term Debt to EBITDA	5.44	3.82	-0.34	-0.20	-0.03	-0.17	0.00	0.00	0.00	0.00
Debt to NOPAT	6.38	5.00	-0.47	-0.28	-0.16	-0.24	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-1.76	-5.86	0.67	1.17	3.01	0.94	0.00	1.02	0.81	2.31
Long-Term Debt to NOPAT	6.38	5.00	-0.47	-0.28	-0.04	-0.24	0.00	0.00	0.00	0.00
Altman Z-Score	6.05	4.51	-6.32	4.42	35.98	-3.61	-11.66	3.16	-1.95	28.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.25	5.92	3.16	5.06	6.99	1.77	2.03	3.34	3.01	8.25
Quick Ratio	4.85	5.00	3.04	4.84	6.91	1.66	1.77	3.03	2.66	7.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-74	-67	-154	-252	-208	-90	-95	-74	-47	-42
Operating Cash Flow to CapEx	-90,037.78%	0.00%	-1,258,357.14%	-73,724.19%	-60,085.99%	-101,378.63%	-143,250.00%	-4,688,000.00%	-18,358.43%	-105,858.47%
Free Cash Flow to Firm to Interest Expense	-3.06	-5.35	-15.10	-44.72	-32.89	-17.09	-108.78	-88.10	0.00	0.00
Operating Cash Flow to Interest Expense	-1.69	-2.49	-17.29	-52.44	-33.89	-25.12	-147.01	-110.96	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-1.69	-2.49	-17.29	-52.51	-33.95	-25.14	-147.11	-110.96	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.73	0.89	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	3.65	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	6.14	12.38	0.40	0.57	0.61	0.53	0.81	4.52
Accounts Payable Turnover	0.80	0.35	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	712.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	458.87	1,039.52	0.00	20,400.27	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	353.76	-1,039.52	0.00	-20,400.27	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	155	43	-44	-45	-56	-73	-45	-18	-9.53	-1.03
Invested Capital Turnover	3.32	-374.46	-0.06	-0.13	0.00	0.00	0.00	-0.01	-0.03	282.45
Increase / (Decrease) in Invested Capital	112	87	1.02	11	17	-28	-27	-8.65	-8.51	-2.05
Enterprise Value (EV)	4,618	2,469	1,616	2,433	6,265	994	271	495	210	525
Market Capitalization	4,686	2,586	1,719	2,716	6,840	1,105	340	579	254	627
Book Value per Share	$1.43	$1.06	$0.40	$1.66	$3.95	$0.39	$0.29	$0.95	$0.66	$1.93
Tangible Book Value per Share	$1.43	$1.06	$0.40	$1.65	$3.94	$0.38	$0.28	$0.94	$0.64	$1.92
Total Capital	467	261	130	305	549	68	24	67	36	102
Total Debt	244	100	71	68	30	29	0.00	0.13	0.07	0.21
Total Long-Term Debt	244	100	71	67	7.72	29	0.00	0.00	0.00	0.00
Net Debt	-67	-117	-103	-283	-576	-111	-69	-85	-45	-102
Capital Expenditures (CapEx)	0.05	0.00	0.01	0.40	0.36	0.13	0.09	0.00	0.34	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	165	47	-47	-48	-59	-76	-29	-19	-11	-0.67
Debt-free Net Working Capital (DFNWC)	476	264	115	267	546	65	40	65	34	77
Net Working Capital (NWC)	476	264	115	266	524	65	40	65	34	76
Net Nonoperating Expense (NNE)	15	7.34	71	107	88	55	51	35	23	19
Net Nonoperating Obligations (NNO)	-67	-117	-103	-283	-576	-111	-69	-85	-45	-103
Total Depreciation and Amortization (D&A)	-4.71	0.57	2.03	2.09	1.27	0.80	0.10	0.27	0.52	0.55
Debt-free, Cash-free Net Working Capital to Revenue	50.05%	19.99%	-1,673.43%	-720.69%	-38,855.92%	-49,824.34%	-18,897.37%	-12,650.00%	-7,125.37%	-440.63%
Debt-free Net Working Capital to Revenue	144.58%	113.08%	4,131.89%	3,984.99%	359,450.66%	42,567.11%	26,432.24%	43,084.87%	22,404.33%	50,240.13%
Net Working Capital to Revenue	144.58%	113.08%	4,131.89%	3,970.41%	344,859.21%	42,567.11%	26,432.24%	43,000.66%	22,359.02%	50,101.30%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.16	$0.09	($1.46)	($2.63)	($2.42)	($1.96)	($2.30)	($1.91)	($1.60)	($1.38)
Adjusted Weighted Average Basic Shares Outstanding	145.32M	141.96M	135.41M	142.82M	140.59M	109.40M	83.87M	75.58M	56.91M	54.10M
Adjusted Diluted Earnings per Share	$0.15	$0.09	($1.46)	($2.63)	($2.42)	($1.96)	($2.30)	($1.91)	($1.60)	($1.38)
Adjusted Weighted Average Diluted Shares Outstanding	160.34M	148.51M	135.41M	142.82M	140.59M	109.40M	83.87M	75.58M	56.91M	54.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($2.63)	($2.42)	($1.96)	($2.30)	($1.91)	($1.60)	($1.38)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	157.07M	154.42M	146.36M	132.22M	115.33M	88.37M	75.47M	62.07M	49.04M	45.65M
Normalized Net Operating Profit after Tax (NOPAT)	38	20	-153	-241	-192	-118	-122	-83	-55	-44
Normalized NOPAT Margin	11.64%	8.57%	-5,487.30%	-3,608.00%	-125,997.24%	-77,854.28%	-80,315.79%	-54,670.00%	-36,367.30%	-29,023.31%
Pre Tax Income Margin	7.78%	5.59%	-8,036.34%	-5,204.08%	-183,803.29%	-113,730.92%	-114,132.89%	-77,944.74%	-51,482.24%	-41,310.04%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.07	2.04	-20.96	-60.74	-43.14	-31.70	-196.81	-139.21	0.00	0.00
NOPAT to Interest Expense	1.59	1.59	-15.00	-42.81	-30.26	-22.38	-139.20	-98.34	0.00	0.00
EBIT Less CapEx to Interest Expense	2.06	2.04	-20.96	-60.81	-43.20	-31.72	-196.92	-139.21	0.00	0.00
NOPAT Less CapEx to Interest Expense	1.59	1.59	-15.00	-42.88	-30.32	-22.41	-139.30	-98.34	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	37.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from TG Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	146.04%	-49.41%	357.05%	713.46%	54,183.95%	176,298.94%	2,606.06%	287.05%	-96.51%	-95.37%
EBITDA Growth	350.48%	-88.36%	121.73%	74.14%	83.51%	450.35%	-17.61%	45.07%	17.97%	59.89%
EBIT Growth	379.29%	-87.16%	123.94%	76.94%	84.66%	444.29%	-17.31%	45.16%	18.05%	59.61%
NOPAT Growth	414.12%	-90.15%	129.60%	74.94%	83.90%	569.00%	-14.72%	44.68%	16.58%	58.93%
Net Income Growth	261.84%	-96.59%	114.45%	72.71%	81.63%	418.08%	-17.53%	43.15%	15.93%	58.17%
EPS Growth	0.00%	-97.26%	111.76%	0.00%	0.00%	380.77%	-13.33%	0.00%	17.14%	60.00%
Operating Cash Flow Growth	-94.10%	-114.58%	113.18%	86.30%	44.66%	342.66%	14.48%	12.79%	72.53%	48.67%
Free Cash Flow Firm Growth	12.26%	-191.05%	-1.84%	-36.56%	-73.99%	203.73%	-34.45%	-1.82%	27.11%	14.06%
Invested Capital Growth	259.49%	172.75%	1,016.85%	419.07%	197.19%	226.96%	80.03%	63.35%	2.25%	49.54%
Revenue Q/Q Growth	28.98%	14.17%	15.74%	44.36%	-73.48%	931.57%	106.00%	9,533.33%	-13.83%	-84.18%
EBITDA Q/Q Growth	125.65%	45.79%	201.07%	24.67%	-110.49%	372.05%	-20.32%	27.36%	-122.86%	8.68%
EBIT Q/Q Growth	114.46%	43.43%	225.48%	27.64%	-109.86%	367.47%	-20.87%	27.42%	-121.27%	8.86%
NOPAT Q/Q Growth	142.86%	22.10%	242.66%	25.75%	-107.61%	467.05%	-20.77%	28.95%	-121.78%	10.22%
Net Income Q/Q Growth	501.31%	-43.60%	164.25%	25.73%	-112.65%	339.30%	-21.36%	25.97%	-119.08%	11.58%
EPS Q/Q Growth	0.00%	-50.00%	0.00%	0.00%	0.00%	314.71%	0.00%	0.00%	-123.08%	13.33%
Operating Cash Flow Q/Q Growth	-110.09%	-320.47%	167.45%	37.87%	-115.78%	299.27%	29.88%	-150.95%	30.80%	29.77%
Free Cash Flow Firm Q/Q Growth	-74.69%	18.64%	18.17%	24.55%	-281.27%	191.00%	-9.72%	-41.89%	-8.07%	-17.95%
Invested Capital Q/Q Growth	64.62%	52.08%	23.00%	16.74%	24.90%	611.23%	57.20%	64.44%	-63.15%	19.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	77.13%	100.00%	88.70%	91.43%	77.79%	97.88%	100.00%	89.02%	420.99%	100.00%
EBITDA Margin	28.70%	16.41%	12.85%	-14.71%	-28.19%	71.28%	-270.28%	-462.73%	-92,816.05%	-35,888.30%
Operating Margin	27.68%	14.82%	12.00%	-14.60%	-28.39%	69.22%	-277.93%	-474.07%	-95,728.40%	-37,194.68%
EBIT Margin	29.93%	18.00%	14.33%	-13.22%	-26.37%	70.95%	-273.63%	-466.33%	-93,344.44%	-36,351.06%
Profit (Net Income) Margin	21.57%	4.63%	9.36%	-16.87%	-32.79%	68.71%	-296.19%	-502.78%	-96,877.78%	-38,104.26%
Tax Burden Percent	91.66%	90.91%	105.01%	100.27%	102.78%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	78.60%	28.26%	62.22%	127.27%	120.97%	96.84%	108.25%	107.82%	103.79%	104.82%
Effective Tax Rate	8.34%	9.09%	-5.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	84.29%	55.47%	158.43%	-171.19%	0.00%	3,584.90%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	88.75%	61.97%	161.35%	-165.68%	0.00%	3,585.56%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-42.83%	-39.63%	-120.53%	135.15%	0.00%	-3,486.49%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	41.46%	15.84%	37.90%	-36.04%	11.57%	98.41%	-207.28%	-170.41%	-151.36%	-115.86%
Cash Return on Invested Capital (CROIC)	-74.27%	-93.24%	53.45%	-36.23%	-156.46%	-217.19%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	21.71%	10.40%	15.98%	-13.40%	-23.56%	49.05%	-27.86%	-15.98%	-907.06%	-582.12%
Return on Assets (ROA)	15.64%	2.67%	10.44%	-17.10%	-29.29%	47.51%	-30.15%	-17.23%	-941.40%	-610.20%
Return on Common Equity (ROCE)	41.46%	15.84%	37.90%	-36.04%	11.57%	98.41%	-207.28%	-170.41%	-151.36%	-115.86%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-7.48%	53.89%	25.73%	0.00%	-15.72%	-434.22%	-614.42%	0.00%	-237.54%
Net Operating Profit after Tax (NOPAT)	27	11	9.26	-6.49	-8.74	115	-31	-26	-54	-24
NOPAT Margin	25.38%	13.48%	12.60%	-10.22%	-19.88%	69.22%	-194.55%	-331.85%	-67,009.88%	-26,036.28%
Net Nonoperating Expense Percent (NNEP)	-4.46%	-6.50%	-2.92%	-5.51%	-5.15%	-0.66%	-15.56%	-10.39%	-12.55%	-4.60%
Return On Investment Capital (ROIC_SIMPLE)	5.88%	-	-	-	-3.35%	-	-	-	-41.84%	-
Cost of Revenue to Revenue	22.87%	0.00%	11.30%	8.57%	22.21%	2.12%	0.00%	10.98%	-320.99%	0.00%
SG&A Expenses to Revenue	36.01%	50.03%	52.80%	54.48%	70.85%	19.76%	191.09%	359.71%	59,238.27%	15,163.83%
R&D to Revenue	22.07%	24.01%	23.90%	51.55%	39.68%	8.90%	174.95%	203.38%	36,586.42%	22,128.72%
Operating Expenses to Revenue	49.45%	85.18%	76.70%	106.03%	106.19%	28.66%	377.93%	563.09%	96,149.38%	37,294.68%
Earnings before Interest and Taxes (EBIT)	32	15	11	-8.39	-12	118	-44	-36	-76	-34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	31	14	9.44	-9.34	-12	118	-43	-36	-75	-34
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	21.07	18.85	15.48	14.67	16.11	7.66	91.74	80.24	29.35	8.56
Price to Tangible Book Value (P/TBV)	21.07	18.85	15.48	14.74	16.11	7.70	93.58	82.65	29.75	8.63
Price to Revenue (P/Rev)	14.24	13.68	7.93	8.12	11.07	6.65	154.29	256.80	617.38	171.15
Price to Earnings (P/E)	200.38	0.00	28.73	57.01	204.08	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.50%	0.00%	3.48%	1.75%	0.49%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	29.80	37.42	42.54	44.49	57.26	32.79	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	14.04	13.31	7.60	7.74	10.57	5.96	152.33	251.76	580.41	145.74
Enterprise Value to EBITDA (EV/EBITDA)	102.82	2,406.63	24.87	42.24	94.07	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	93.07	624.37	24.34	41.71	96.14	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	120.56	0.00	25.88	46.77	123.33	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	38.83	110.39	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	79.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.10	1.27	0.58	0.63	0.62	0.60	2.42	3.52	1.21	0.70
Long-Term Debt to Equity	1.10	1.27	0.58	0.63	0.62	0.60	2.42	3.52	1.21	0.70
Financial Leverage	-0.48	-0.64	-0.75	-0.82	-1.01	-0.97	-1.24	-1.30	-1.30	-1.20
Leverage Ratio	2.37	2.57	2.85	3.04	2.39	2.07	2.79	2.53	1.94	1.52
Compound Leverage Factor	1.86	0.73	1.78	3.87	2.89	2.00	3.02	2.73	2.01	1.60
Debt to Total Capital	52.36%	55.96%	36.61%	38.76%	38.42%	37.51%	70.72%	77.87%	54.84%	41.07%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	52.36%	55.96%	36.61%	38.76%	38.42%	37.51%	70.72%	77.87%	54.84%	41.07%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	47.64%	44.04%	63.39%	61.24%	61.58%	62.49%	29.28%	22.13%	45.16%	58.93%
Debt to EBITDA	5.44	166.77	0.97	1.91	3.82	-8.94	-0.60	-0.62	-0.34	-0.31
Net Debt to EBITDA	-1.50	-66.95	-1.09	-2.07	-4.47	11.77	0.29	0.28	0.49	0.56
Long-Term Debt to EBITDA	5.44	166.77	0.97	1.91	3.82	-8.94	-0.60	-0.62	-0.34	-0.31
Debt to NOPAT	6.38	-690.69	1.01	2.12	5.00	-7.46	-0.83	-0.85	-0.47	-0.43
Net Debt to NOPAT	-1.76	277.25	-1.14	-2.29	-5.86	9.82	0.40	0.38	0.67	0.78
Long-Term Debt to NOPAT	6.38	-690.69	1.01	2.12	5.00	-7.46	-0.83	-0.85	-0.47	-0.43
Altman Z-Score	5.95	3.26	3.73	2.43	4.14	0.90	2.30	-3.16	-3.96	-4.76
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.25	4.59	3.58	3.62	5.92	5.53	2.87	2.93	3.16	5.02
Quick Ratio	4.85	3.65	2.77	2.76	5.00	4.65	2.23	2.35	3.04	4.83
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-84	-48	-59	-73	-96	53	-58	-53	-55	-51
Operating Cash Flow to CapEx	-122,100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-795,666.67%	-862,375.00%
Free Cash Flow to Firm to Interest Expense	-12.18	-4.46	-14.94	-31.73	-39.58	14.29	-16.08	-18.69	-19.32	-31.05
Operating Cash Flow to Interest Expense	-3.70	-1.13	1.39	-3.59	-5.43	22.54	-11.58	-21.06	-8.34	-20.93
Operating Cash Flow Less CapEx to Interest Expense	-3.70	-1.13	1.39	-3.59	-5.43	22.54	-11.58	-21.06	-8.34	-20.93
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.73	0.58	1.11	1.01	0.89	0.69	0.10	0.03	0.01	0.02
Accounts Receivable Turnover	3.65	3.42	6.86	7.86	0.00	0.00	2.74	1.80	0.00	0.00
Inventory Turnover	0.51	0.40	0.48	0.36	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	1,909.79	0.00	745.67	73.67	22.47	6.14	10.30
Accounts Payable Turnover	0.80	0.33	0.35	0.26	0.35	0.13	0.02	0.02	0.00	0.01
Days Sales Outstanding (DSO)	100.00	106.86	53.21	46.43	0.00	0.00	133.33	202.81	0.00	0.00
Days Inventory Outstanding (DIO)	712.63	917.72	752.97	1,023.33	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	458.87	1,095.68	1,056.52	1,407.71	1,039.52	2,900.42	21,207.47	22,015.48	0.00	28,838.87
Cash Conversion Cycle (CCC)	353.76	-71.10	-250.34	-337.96	-1,039.52	-2,900.42	-21,074.14	-21,812.67	0.00	-28,838.87
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	155	94	62	50	43	35	-6.75	-16	-44	-27
Invested Capital Turnover	3.32	4.12	12.57	16.75	-374.46	51.79	-1.19	-0.29	-0.06	-0.12
Increase / (Decrease) in Invested Capital	112	60	69	66	87	62	27	27	1.02	27
Enterprise Value (EV)	4,618	3,523	2,634	2,239	2,469	1,132	3,664	2,158	1,616	732
Market Capitalization	4,686	3,621	2,749	2,349	2,586	1,262	3,711	2,201	1,719	860
Book Value per Share	$1.43	$1.24	$1.15	$1.04	$1.06	$1.09	$0.27	$0.19	$0.40	$0.69
Tangible Book Value per Share	$1.43	$1.24	$1.15	$1.03	$1.06	$1.09	$0.27	$0.18	$0.40	$0.69
Total Capital	467	436	280	261	261	264	138	124	130	171
Total Debt	244	244	103	101	100	99	98	97	71	70
Total Long-Term Debt	244	244	103	101	100	99	98	97	71	70
Net Debt	-67	-98	-116	-110	-117	-130	-47	-43	-103	-128
Capital Expenditures (CapEx)	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	165	108	63	51	47	32	-9.00	-18	-47	-29
Debt-free Net Working Capital (DFNWC)	476	449	280	261	264	261	136	122	115	146
Net Working Capital (NWC)	476	449	280	261	264	261	136	122	115	146
Net Nonoperating Expense (NNE)	4.12	7.42	2.38	4.22	5.68	0.85	16	13	24	11
Net Nonoperating Obligations (NNO)	-67	-98	-116	-110	-117	-130	-47	-43	-103	-128
Total Depreciation and Amortization (D&A)	-1.33	-1.34	-1.09	-0.95	-0.80	0.55	0.54	0.28	0.43	0.44
Debt-free, Cash-free Net Working Capital to Revenue	50.05%	40.75%	18.24%	17.67%	19.99%	17.01%	-37.41%	-210.02%	-1,673.43%	-586.41%
Debt-free Net Working Capital to Revenue	144.58%	169.55%	80.90%	90.17%	113.08%	137.76%	565.05%	1,419.82%	4,131.89%	2,914.93%
Net Working Capital to Revenue	144.58%	169.55%	80.90%	90.17%	113.08%	137.76%	565.05%	1,419.82%	4,131.89%	2,914.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.15	$0.03	$0.05	($0.07)	($0.09)	$0.80	($0.34)	($0.28)	($0.58)	($0.26)
Adjusted Weighted Average Basic Shares Outstanding	145.32M	145.10M	144.73M	146.21M	141.96M	142.87M	141.50M	140.31M	135.41M	135.33M
Adjusted Diluted Earnings per Share	$0.00	$0.02	$0.04	$0.00	$0.00	$0.73	($0.34)	($0.28)	($0.58)	($0.26)
Adjusted Weighted Average Diluted Shares Outstanding	160.34M	160.71M	159.42M	154.54M	148.51M	155.87M	141.50M	140.31M	135.41M	135.33M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	157.07M	155.67M	154.82M	154.54M	154.42M	151.41M	150.98M	149.40M	146.36M	145.34M
Normalized Net Operating Profit after Tax (NOPAT)	27	11	6.17	-6.49	-8.74	80	-31	-26	-54	-24
Normalized NOPAT Margin	25.38%	13.48%	8.40%	-10.22%	-19.88%	48.46%	-194.55%	-331.85%	-67,009.88%	-26,036.28%
Pre Tax Income Margin	23.53%	5.09%	8.92%	-16.82%	-31.90%	68.71%	-296.19%	-502.78%	-96,877.78%	-38,104.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	4.67	1.39	2.65	-3.67	-4.77	31.68	-12.13	-12.79	-26.42	-20.73
NOPAT to Interest Expense	3.96	1.04	2.33	-2.84	-3.60	30.91	-8.62	-9.10	-18.97	-14.85
EBIT Less CapEx to Interest Expense	4.67	1.39	2.65	-3.67	-4.77	31.68	-12.13	-12.79	-26.42	-20.74
NOPAT Less CapEx to Interest Expense	3.96	1.04	2.33	-2.84	-3.60	30.91	-8.62	-9.10	-18.97	-14.85
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	37.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About TG Therapeutics' Financials

When does TG Therapeutics's fiscal year end?

According to the most recent income statement we have on file, TG Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has TG Therapeutics' net income changed over the last 9 years?

Over the last 9 years, TG Therapeutics' net income changed from -$62.95 million in 2015 to $23.38 million in 2024, a change of -137.1%. See TG Therapeutics' forecast for analyst expectations on what’s next for the company.

What is TG Therapeutics's operating income?

TG Therapeutics's total operating income in 2024 was $41.93 million, based on the following breakdown:

Total Gross Profit: $290.52 million
Total Operating Expenses: $248.59 million

How has TG Therapeutics revenue changed over the last 9 years?

Over the last 9 years, TG Therapeutics' total revenue changed from $152.38 thousand in 2015 to $329.00 million in 2024, a change of 215,808.8%.

How much debt does TG Therapeutics have?

TG Therapeutics' total liabilities were at $355.33 million at the end of 2024, a 110.1% increase from 2023, and a 2,886.0% increase since 2015.

How much cash does TG Therapeutics have?

In the past 9 years, TG Therapeutics' cash and equivalents has ranged from $25.03 million in 2016 to $553.44 million in 2020, and is currently $179.89 million as of their latest financial filing in 2024.

How has TG Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, TG Therapeutics' book value per share changed from 1.93 in 2015 to 1.43 in 2024, a change of -26.1%.

Related Companies

This page (NASDAQ:TGTX) was last updated on 6/3/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Financials

Frequently Asked Questions About TG Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Financials

Annual Income Statements for TG Therapeutics

Quarterly Income Statements for TG Therapeutics

Annual Cash Flow Statements for TG Therapeutics

Quarterly Cash Flow Statements for TG Therapeutics

Annual Balance Sheets for TG Therapeutics

Quarterly Balance Sheets for TG Therapeutics

Annual Metrics And Ratios for TG Therapeutics

Quarterly Metrics And Ratios for TG Therapeutics

Frequently Asked Questions About TG Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools